Reported revenues of $227.2m, down 17% on 1HFY19
• Reported EBITDA of $34.6m, a decrease of 47% on 1HFY19
• Underlying EBITDA of $47.4m, a decrease of 42% on 1HFY19
• Reported net loss after tax of $17.5m driven by lower earnings and restructuring expenses
• Net operating cashflow of $46.2m down 14% on 1HFY19
• Licensed novel oral contraceptive E4/DRSP in the US
• Generic NUVARING® complete response letter submitted to the US Food and Drug
Administration (FDA) with launch anticipated in CY20
• Filed three generic products with the FDA including a potential first-to-market women’s health
product
• Significant spend base reduction of $20m (annualised)
Reported revenues of $227.2m, down 17% on 1HFY19• Reported...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$5.00 |
Change
0.000(0.00%) |
Mkt cap ! $406.2M | |||
| Open | High | Low | Value | Volume |
| $4.99 | $5.07 | $4.96 | $1.626M | 325.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2153 | $4.99 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $5.00 | 7764 | 1 |
View Market Depth
| Last trade - 16.12pm 01/07/2025 (20 minute delay) ? |
| MYX (ASX) Chart |